Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac potassium, quantity: 50 mg - tablet, sugar coated - excipient ingredients: colloidal anhydrous silica; calcium phosphate; magnesium stearate; maize starch; povidone; sodium starch glycollate; microcrystalline cellulose; iron oxide red; macrogol 8000; sucrose; purified talc; titanium dioxide - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Australia - English - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - diclofenac potassium, quantity: 12.5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; stearic acid; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; povidone; microcrystalline cellulose; magnesium stearate; maize starch; hypromellose - temporary relief of painful conditions such as headache, dental pain, period pain, rheumatic and muscular pain, backache. temporary relief of symptoms of colds and flu (including aches and pains, sore throat pain). reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis consumer health australasia pty ltd - diclofenac potassium -

Australia - English - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - diclofenac potassium, quantity: 25 mg - tablet, sugar coated - excipient ingredients: macrogol 8000; iron oxide red; sucrose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; purified talc; maize starch; povidone; calcium phosphate; microcrystalline cellulose; titanium dioxide - as short-term treatment (up to one week) for the relief of acute pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea. indications as at 16 november 1998: as short-term treatment (up to one week) for the relief of acute pain states in which there is an inflammatory component. treatment of acute migraine attacks (with or without aura). symptomatic treatment of primary dysmenorrhoea.

United States - English - NLM (National Library of Medicine)

direct rx - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 10 mg in 1 g - voltaren® gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. - voltaren® gel has not been evaluated for use on the spine, hip, or shoulder. the use of voltaren® gel is contraindicated in patients with a known hypersensitivity to diclofenac. voltaren® gel should not be administered in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.1)]. voltaren® gel is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. 8.1 pregnancy the safety of voltaren® gel has not been established during pregnancy. there are no well-controlled studies of diclofenac in pregnant women. human and animal studies indicate that diclofenac crosses the placenta. in late pregnancy, as with othe

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; macrogol 8000; purified talc; iron oxide red; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate; magnesium stearate; povidone; titanium dioxide; peg-40 hydrogenated castor oil; hypromellose; sodium starch glycollate; methacrylic acid copolymer; maize starch; steareth-2; simethicone; sorbic acid - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: macrogol 8000; iron oxide yellow; peg-40 hydrogenated castor oil; acrylates copolymer; maize starch; sodium starch glycollate; purified talc; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; magnesium stearate; povidone; lactose monohydrate; titanium dioxide; steareth-2; simethicone; sorbic acid - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 50 mg - suppository, moulded - excipient ingredients: hydrogenated coco-glycerides; hard fat - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 25 mg - suppository, moulded - excipient ingredients: hydrogenated coco-glycerides; hard fat - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 12.5 mg - suppository, moulded - excipient ingredients: hydrogenated coco-glycerides; hard fat - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. short term (up to three days) treatment of post-operative pain in children.